To Compare the renoprotective effect of sitagliptin and vildagliptin for patient with type 2 diabetic nephropathy

To Compare the renoprotective effect of sitagliptin and vildagliptin for patient with type 2 diabetic nephropathy - To Compare the renoprotective effect of sitagliptin and vildagliptin for patient with type 2 diabetic nephropathy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011678

Enrollment

Registered

2013-09-07

Start date

2013-04-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

sitagliptin vildagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who give informed consent

Exclusion criteria

Exclusion criteria: Patients who has contraindication with sitagliptin Patients who has contraindication with vildagliptin Patients who judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Renal profile at 16 and 52 weeks after administration.	—

Secondary

Measure	Time frame
Glucose profile at 16 and 52 weeks after administration. Lipid profile at 16 and 52 weeks after administration.	—

Countries

Japan

Contacts

Public ContactSatoshi Ito

Machida Municipal Hospital Endocrine/diabetes

s.itou@machida-city-hp.jp0427-22-2230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026